Kenny and Bissell (2007) showed that inhibition of TACE protease activity blocked EGFR signalling, resulting in a reversion of the malignant phenotype of T4-2 breast cancer cells. Inhibition of TACE using selective inhibitors also decreased cell proliferation in an in vitro model of colorectal cancer (Merchant et al, 2008). Here, ADAM17 is linked to breast carcinoma.